Why Aphria Inc. Ought to Ditch TSX

Aphria Inc. (TSX:APH), one of the best run Canadian cannabis companies, ought to call the TSX’s bluff and move to another exchange. 

| More on:

Two of my Fool.ca colleagues recently warned that Aphria Inc. (TSX:APH) is playing with fire by holding interests in U.S. cannabis businesses because that potentially puts it offside with both the U.S. Attorney General’s office and the mighty Toronto Stock Exchange.

I have three words for Aphria CEO Vic Neufeld: Call their bluff!

What’s the real risk here?

I believe in assessing stocks based on what I know rather than speculation by others. In recent months there has been a great deal of chatter about the TSX rattling its sword to keep all of its listed companies in line.

The TSX is concerned about Aphria because of its dealings in the U.S. — a nation so hopelessly divided at the moment that the exchange is concerned that Neufeld will be thrown in jail south of the border — taking the good name of the exchange down with him.

I’m being facetious, of course, but in my opinion, the exchange ought to stay out of Aphria’s business for two reasons.

“The U.S. government continues to take a tough stance on marijuana, and Attorney General Jeff Sessions only further complicated things when he stated that federal laws on pot could still be enforced in states where the drug has been legalized,” wrote David Jagielski on January 12. “This legal ambiguity creates a lot of uncertainty for investors, and it’s hard to understand why Aphria would risk running into problems down the road.”

No legitimate business wants to run afoul of the law, especially not a growing cannabis company with a market cap of $3.5 billion.

However, Americans take state rights very seriously.

In a recent poll by HuffPost/YouGov, only 30% of Americans said they would back a move by federal prosecutors to stop the sale and use of marijuana in states where pot is legal. Aphria’s U.S. investments are in Florida and Arizona, where medical marijuana is legal.

Jeff Sessions can do and say whatever he wants, but should the rights of Americans be trampled upon in states where medical and recreational marijuana is legal, you can be sure that there will be years of litigation and court proceedings to protect those rights.

What about the TSX?

As I said earlier, the TSX ought to mind its own business. There’s a difference between believing a listed company is doing something illegal and a lawyer’s opinion that they could be.

However, if the TSX continues to play a game of chicken, I believe that Neufeld ought to take his company’s business elsewhere. There are places to list right here in Canada that would gladly have it — the Canadian Securities Exchange being one; Aequitas Neo Exchange being another. 

The CSE has 53 cannabis issuers listed on its exchange; 17 of them doing business in the U.S. Those 17 companies account for 25% of the CSE’s entire market cap. I’m sure CSE CEO Richard Carlton would have no problem welcoming Aphria into the fold. 

Fool.ca contributor Joey Frenette likens Aphria’s situation to Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) in that Aphria could be forced to sell its U.S. assets quickly at prices that are less than optimal in order to comply with TSX rules and the U.S. Attorney General.

I fail to see how one has anything to do with the other.

Valeant had to unload assets or its bankers would have come calling, hat in hand.

Aphria, on the other hand, has done everything to comply with the laws in the jurisdictions in which they operate. There’s almost zero chance that the company would not be given an opportunity to sell those assets in a way that meets the needs of shareholders.

Chances are, however, it won’t come to that.

Bottom line

The TSX is proving once more why exchanges like the CSE are growing in stature. The TSX’s sabre rattling is both perplexing and counterproductive to building an entrepreneurial, pro-business environment for companies to raise capital in this country.

Take a pass on Aphria stock if you must, but don’t let your decision be guided by conjecture and speculation because at the end of the day, Aphria does have options — good ones, in fact.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Will Ashworth has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

tsx today
Stock Market

TSX Today: Why Record-Breaking Rally Could Extend on Thursday, March 28

The main TSX index closed above the 22,000 level for the first time yesterday and remains on track to post…

Read more »

Nuclear power station cooling tower
Metals and Mining Stocks

If You’d Invested $1,000 in Cameco Stock 5 Years Ago, This Is How Much You’d Have Now

Cameco (TSX:CCO) stock still looks undervalued, despite a 258% rally. Can the uranium miner deliver more capital gains to shareholders?

Read more »

Businessman holding tablet and showing a growing virtual hologram of statistics, graph and chart with arrow up on dark background. Stock market. Business growth, planning and strategy concept
Dividend Stocks

TFSA Magic: Earn Enormous Passive Income That the CRA Can’t Touch

If you're seeking out passive income, with zero taxes involved, then get on board with a TFSA and this portfolio…

Read more »

Man with no money. Businessman holding empty wallet
Dividend Stocks

2 Stocks Under $50 New Investors Can Confidently Buy

There are some great stocks under $50 that every investor needs to know about. Here’s a look at two great…

Read more »

potted green plant grows up in arrow shape
Stocks for Beginners

3 Growth Stocks I’m Buying in April

These three growth stocks are up in the last year, and that is likely to continue on as we keep…

Read more »

clock time
Tech Stocks

Long-Term Investing: 3 Top Canadian Stocks You Can Buy for Under $20 a Share

These three under-$20 stocks offer excellent buying opportunities for long-term investors.

Read more »

Arrowings ascending on a chalkboard
Energy Stocks

Beat the TSX With This Cash-Gushing Dividend Stock

Canadian Natural Resources stock is well set up to beat the TSX as it continues to generate strong cash flows…

Read more »

think thought consider
Dividend Stocks

Down 10.88%: Is ATD Stock a Good Buy After Earnings?

Alimentation Couche-Tard (TSX:ATD) stock might not be the easy buy-case it once was. Here’s a look at what happened.

Read more »